Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

118.53USD
22 Jun 2017
Change (% chg)

-- (--)
Prev Close
$118.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
422,550
52-wk High
$121.75
52-wk Low
$81.13

EW.N

Chart for EW.N

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $24,867.93
Shares Outstanding(Mil.): 209.80
Dividend: --
Yield (%): --

Financials

BRIEF-Neovasc says German Court partially found in favor of Edwards Lifesciences in its case against co

* District court in Munich has partially found in favour of Edwards Lifesciences Corporation in its case against Neovasc

16 Jun 2017

BRIEF-Edwards Lifesciences says SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures

* Edwards SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures Source text for Eikon: Further company coverage:

06 Jun 2017

FDA approves new use for Edwards' Sapien 3 heart valve

The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

06 Jun 2017

UPDATE 1-FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

06 Jun 2017

FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

06 Jun 2017

BRIEF-Edwards Lifesciences Q1 earnings per share $1.06

* Says Q1 earnings per share $1.06; Q1 adjusted earnings per share $0.94; Q1 sales grew 27 percent to $884 million

26 Apr 2017

Edwards profit tops expectations on soaring heart valve sales

April 25 Edwards Lifesciences Corp on Tuesday reported higher-than expected first-quarter profit and revenue on surging sales of transcatheter heart valve replacements, and raised its full-year earnings forecast to reflect the strong start to the year.

26 Apr 2017

BRIEF-German patent court issues initial decision

* District court in Germany ruled that Boston Scientific's lotus valve infringes one of co's patents for transcatheter aortic valves

09 Mar 2017

BRIEF-Boston Scientific receives favorable rulings in Edwards Lifesciences litigation

* Boston scientific receives favorable rulings in edwards lifesciences litigation

09 Mar 2017

Edwards Lifesciences 4th-quarter sales, profit top expectations

Feb 1 Edwards Lifesciences Corp on Wednesday reported higher-than-expected fourth-quarter profit and revenue on surging demand for its minimally invasive heart valve replacement systems.

02 Feb 2017

More From Around the Web

Earnings vs. Estimates